High-affinity HLA-A(*)02.01 Peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects

Journal of Immunology

Volumn 169, Issue 9, 2002, Pages 4840-4849

  Francini, Guido ^a   Scardino, Antonio ^a   Kosmatopoulos, Kostas ^a   Lemonnier, François A ^a   Campoccia, Giuseppe ^a   Sabatino, Marianna ^a   Pozzessere, Daniele ^a   Petrioli, Roberto ^a   Lozzi, Luisa ^a   Neri, Paolo ^a   Fanetti, Giuseppe ^a   Cusi, Maria Grazia ^a   Correale, Pierpaolo ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; PARATHYROID HORMONE RELATED PROTEIN;

ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BINDING AFFINITY; BONE METASTASIS; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MALE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; TRANSGENIC MOUSE; TUMOR IMMUNITY; VACCINATION;

EID: 0036839142     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.9.4840     Document Type: Article

References (50)

1. Wolfel, T., E. Klehmann, C. Muller, K. H. Schutt, K. H. Meyer Zum Buschenfelde, and A. Knuth. 1989. Lysis of human melanoma cells by autologous cytolytic T cell clones: identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J. Exp. Med. 170:797.
2. Crowley, N. J., T. L. Darrow, M. A. Quinn-Allen, and H. F. Seigler. 1991. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells: evidence for restriction by a dominant HLA-A allele. J. Immunol. 146:1692.
3. Falk, K., O. Rötzschke, S. Stevanovic, and H. G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290.
4. Hunt, D. F., R. A. Henderson, J. Shabanowitz, K. Sakaguchi, H. Michel, N. Sevilir, A. L. Cox, E. Appella, and V. H. Enghelard. 1992. Characterization of peptides bound to the class 1 MHC molecule HLA-A(*)02.01 by mass spectrometry. Science 255:1261.
5. Van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science 254:1643.
6. Tsang, K. Y., S. Zaremba, C. A. Nieroda, M. Z. Zhu, J. M. Hamilton, and J. Schlom. 1995. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia CEA vaccine. J. Natl. Cancer Inst. 87:982.
7. ras-derived synthetic peptides. Vaccine Res. 3:183.
8. Jung, S., and H. J. Schluesener. 1991. Human T lymphocytes recognize a peptide of single point-mutated oncogene ras proteins. J. Exp. Med. 173:273.
9. Fenton, R. G., D. D. Taub, L. W. Kwak, M. R. Smith. and D. L. Longo. 1993. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated fas proto-oncogenes. J. Natl. Cancer Inst. 85:1294.
10. + T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. Eur. J. Immunol. 25:2588.
11. Correale, P., K. Waimsley, C. Nieroda, S. Zaremba, M. Zhu, J. Schlom, and K. Y. Tsang. 1997, In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst. 89:293.
12. Houbiers, J. G., H. W. Nijman, S. H. van der Burg, J. W. Drijfhout, P, Kenemens, C. J. van de Velde, M. Brand, F. Momberg, W. M. Kast, and C. J. M. Melief. 1993. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23:2072.
13. Van Pel, A., P, van der Bruggen, P. G. Coulie, V. G. Brichard, B. Lethe, B. van den Eynde, C. Uyttenhove, J. C. Renauld, and T. Boon. 1995. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 145:229.
14. Robbins, P. F., and Y. Kawakami. 1996. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 8:628.
15. Murphy, G., B. Tjioa, H. Ragde, G. Kenny, and A. Boynton. 1996. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29:371.
16. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for treatment of patients with metastatic melanoma. Nat. Med. 4:321.
17. Cibotti, R., J. M. Kannellopoulos, J. P. Cabaniols, O. Halle-Panenko, K. Kosmatopoulos, E. Secarz, and P. Kourilsky. 1992. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc. Natl. Acad. Sci. USA 89:416.
18. Keogh, E., J. Fikes, S. Southwood, E. Celis, R. Chesnut, and A. Sette. 2001. Identification of a new epitopes from four different tumor-associated antigens: Recognition of naturally processed epitopes correlates with HLA*0201-binding affinity. J. Immunol. 167:787.
19. Vinholes, J., R. Coleman, and R. Eastell. 1996. Effects of bone metastases on bone metabolism: Implications, diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat. Rev. 22:289.
20. Hortobagy, G. 1991. Bone metastases in breast cancer patients. Semin. Oncol. 18:11.
21. Rubens, R. D. 1998. Bone metastases: the clinical problem. Eur. J. Cancer 34:210.
22. Mundy, G. R. 1997. Mechanisms of bone metastasis. Cancer 80:1546.
23. Guise, T. A. 1997. Parathyroid hormone-related protein and bone metastases. Cancer 80:1572.
24. Yin, J. J., K. Selander, J. M. Chirgwin, M. Dallas, B. G. Grubbs, R. Wieser, J. Massagué, G. R. Mundy, and T. A. Guise. 1999. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103:197.
25. Yoneda, T. 1998. Cellular and molecular mechanisms of breast and prostate cancer metastases to bone. Eur. J. Cancer 34:240.
26. Vargas, S. J., M. T. Gillespie, G. J. Powell, J. Southby, J. A. Danks, J. M. Moseley, and T. J. Martin. 1992. Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization. J. Bone Min. Res. 7:971.
27. Moseley, J. M., M. Kubota, H. Diefenbach-Jagger, R. E. H. Wettenhall, B. E. Kemp. and L. J Suva. 1987. Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc. Natl. Acad. Sci. USA 84:5048.
28. Lanske, B., M. Amling, L. Neff, J, Guiducci, R. Baron, and H. M. Kronenberg. 1999. Ablation of the PTHrP gene or the PTH/PTHrP receptor gene leads to distinct abnormalities in bone development. J. Clin. Invest. 104:399.
29. Tian, J., M. Smogorzefski, L. Kedes, and S. G Massry. 1993. Parathyroid hormone/parathyroid hormone related protein receptor messenger RNA is present in many tissues besides the kidney. Am. J. Nephrol. 13:210.
30. Suva, L. J., G. A. Winslow, R. E. Wettenhall, R. G. Hammonds, J. M. Moseley, H. Diefenbach Jagger, C. P. Rodda, B. E. Kemp, H. Rodriguez, and E. Y. Chen. 1987. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237:893.
31. Francini, G., R. Petrioli, E. Maioli, S. Gonnelli, S. Marsili, A. Aquino, and S. Bruni. 1993. Hypercalcemia in breast cancer. Clin. Exp. Metastasis 11:359.
32. Grill, V., W. Rankin, and T. G. Martin. 1998. Parathyroid hormone-related protein (PTHrP) and hypercalcaemia. Eur. J. Cancer 34:222.
33. Firat. H., F. Garcia-Pons, S. Tourdot, S. Pascolo, A. Scardino, Z. Garcia, M. L. Michel, R. W. Jack, G. Jung, K. Kosmatopoulos, et al. 1999. H-2 class I knockout, HLA-A2.1-transgenic mice: A versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur. J. Immunol. 29:3112.
34. 2m double knockout mice. J. Exp. Med. 185:2043.
35. Nijman, H. W., J. G. Houbiers, M. P. Vierboom, S. H. van der Burg, J. W. Drijfhout, J. D'Amaro, P. Kenemans, C. J. Melief, and W. M. Kast. 1993. Identification of peptide sequences that potentially trigger HLA-A(*)02.01-restricted cytotoxic T lymphocytes. Eur. J. Immunol. 23:1215.
36. Storkus, W. J., D. N. Howell, R. D. Salter, J. R. Dawson, and P. Creswell. 1987. NK susceptibility varies inversely with target cell class in HLA antigen expression. J. Immunol. 138:1657.
37. Boyum, A. 1968. A one-stage procedure for isolation of granulocytes and lymphocytes from human blood: General sedimentation properties of white blood cells in a 1g gravity field. Scand. J. Clin. Lab. Invest. Suppl. 97:51.
38. Bell, D., J. W. Young, and J. Banchereau. 1999. Dendritic cells. Adv. Immunol. 72:255.
39. Grabbe, S., S. Beissert, T. Schwarz, and R. D. Granstein. 1995. Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy? Immunol. Today 16:117.
40. Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271.
41. Guadagni, F., P. L. Witt, P. F. Robbins, J. Schlom, and W. J. Greiner. 1990. Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-α. Cancer Res. 50:6248.
42. Cusi, M. G., M. Valassina, and P. E. Valensin. 1994. Comparison of MuLV reverse transcriptase and Tth polymerase activity in RT-PCR of samples with low virus burden. BioTechniques 17:1034.
43. Waelti, E. R., and R. Gluck. 1998. Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int. J. Cancer 77:728.
44. Correale, P., M. G. Cusi, M. Sabatino, L. Micheli, D. Pozzessere, C. Nencini, P. E. Valensin, G. Giorgi, R. Zurbriggen, R. Gluck, and G. Francini. 2001. Tumor associated antigen (TAA) specific cytotoxic T cell (CTL) response in vitro and in mouse model, induced by TAA-plasmids delivered by influenza virosomes. Eur. J. Cancer 37:2097.
45. Parker, K. C., M. A. Bednarek, and J. E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152:163.
46. Correale, P., L. Micheli, M. T. Del Vecchio, M. Sabatino, R. Petrioli, D. Pozzessere, S. Marsili, G. Giorgi, L. Lozzi, P. Neri, and G. Francini. 2001. A parathyroid hormone related protein (PTH-rP) specific cytotoxic T cell response induced by in vitro stimulations of tumor infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide loaded autologous dendritic cells and low dose IL-2. Br. J. Cancer 85:1722.
47. Pandian, M. R., C. H. Morgan, E. Carlton, and G. V. Segre. 1992. Modified immunoradiometric assay of parathyroid hormone related protein: Clinical application in the differential diagnosis of hypercalcemia. Clin. Chem. 38:282.
48. Docherty, H. M., M. J. Dixon-Lewis, P. G. Milton, A. Blight, and D. A. Heath. 1989. Parathyroid hormone-related proteins in cultured epithelial cells. J. Endocrinol. 123:487.
49. Cheshire, I. M., A. Blight, W. A. Ratcliffe. and D. W. Proops. 1995. In vitro production of parathyroid hormone related protein by cholesteatoma and normal skin. Clin. Otolaryngol. 20:448.
50. Morimoto, T., G. A. Devora, M. Mibe, M. L. Casey, and P. C. MacDonald. 1997. Parathyroid hormone-related protein and human myometrial cells: Action and regulation. Mol. Cell. Endocrinol. 129:91.